Basic Nimotop Information

• INN (International Nonproprietary Name): Nimodipine
• Brand Names Available In Canada (English): not specified
• ATC Code: C08CA06
• Forms & Dosages: Soft gelatin capsule 30 mg; oral liquid 30 mg/10 mL, 60 mg/10 mL, 60 mg/20 mL in bottles with dosing syringe
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription only (Rx)

Latest Research Highlights

Worried about whether nimodipine still matters after aneurysmal subarachnoid haemorrhage (SAH)?

Recent international meta-analyses and guideline updates from 2022 to 2025 continue to support oral nimodipine for reducing poor neurological outcome and delayed ischemic deficits after aneurysmal SAH.

Canadian randomized controlled trial data during this window remain sparse, with provincial tertiary centres reporting observational series that support current practice.

Key themes across the literature are a confirmatory benefit for oral nimodipine, an ongoing safety focus on hypotension, and repeated emphasis that only oral routes (including nasogastric) are appropriate.

Canadian clinicians flag evidence gaps around access to oral liquid formulations in rural hospitals and formal provincial formulary inclusion for community dispensing.

A practical research recommendation from front-line teams is linkage of a national registry (CIHI-level) to track SAH outcomes with nimodipine exposure and formulary status.

Clinical Effectiveness In Canada

How effective is nimodipine in Canadian practice for preventing post-SAH complications?

Nimodipine’s role in preventing secondary cerebral ischemia after SAH is well established internationally and used as standard care in Canadian neurosurgical ICUs.

Many Canadian hospitals stock branded or generic nimodipine for inpatient use, while community dispensing depends on provincial formularies and discharge prescriptions.

• DIN (Drug Identification Number): uniquely identifies marketed drugs in Canada.
• SAH: Subarachnoid Haemorrhage.

Practical Canadian note: inpatient coverage typically supplies the full 21-day course while outpatient coverage (Ontario Drug Benefit, BC PharmaCare, RAMQ) can require prior authorization or discharge prescriptions.

Pharmacy chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs can dispense nimodipine once DIN and coverage are confirmed.

Start nimodipine within 96 hours post-rupture and continue for 21 days to preserve time-dependent benefit.

Indications And Expanded Uses

Wondering when nimodipine should be used and when it should not?

Approved indication is prevention and treatment of neurological deficits after aneurysmal subarachnoid haemorrhage, which is the only widely accepted evidence-based use.

• Approved Indication: Prevention and treatment of neurological deficits following aneurysmal SAH.
• Off-Label Uses To Avoid Routinely: Migraine prevention and vascular cognitive impairment lack robust RCT support and are not recommended.

Important procedural restriction: only oral administration is permitted — tablets or oral solution, and oral solution via nasogastric tube when required.

Intravenous administration is strictly contraindicated because of reports of severe cardiovascular events and deaths when IV dosing has occurred.

In Canadian emergency departments and neurosurgical units, national or institutional SAH pathways generally include nimodipine as standard therapy.

Any off-label community prescribing should be documented with informed consent and a clear clinical justification, and discharge materials should include bilingual English and French indication and contraindication notes.

Composition And Brand Landscape

Which brands and formulations should pharmacies and prescribers know about?

The active ingredient is nimodipine (INN) and the ATC code is C08CA06, a dihydropyridine calcium channel blocker with cerebral selectivity.

Common formulations to stock include 30 mg capsules and 30–60 mg/10–20 mL oral solutions for NG administration.

Pharmacies should track batch and packaging differences and ensure bilingual labelling in accordance with Canadian requirements when procuring stock.

Contraindications And Special Precautions

Worried about who should not receive nimodipine or who needs extra monitoring?

Absolute contraindications include known hypersensitivity to nimodipine or formulation components and severe hypotension or shock.

Do not administer nimodipine intravenously — this is contraindicated and associated with severe, potentially fatal cardiovascular events.

• Absolute Contraindications: Hypersensitivity; severe hypotension/shock; concomitant strong CYP3A4 inhibitors; IV administration.
• Relative Contraindications/Precautions: Elderly (monitor for hypotension), moderate hepatic impairment (dose reduction and monitoring), pregnancy/breastfeeding (use only if benefits justify risks), and patients in recovery or cultural groups avoiding alcohol where some oral solutions contain alcohol.

Pharmacists should screen for CYP3A4 inhibitors such as certain macrolides and azole antifungals and advise blood-pressure monitoring for the first 48–72 hours after initiation.

When available, offer alcohol-free alternative formulations or explain alcohol content on the product label to patients from Indigenous and recovery communities.

Dosage Guidelines

How should nimodipine be dosed and adjusted in typical Canadian patients?

The standard adult regimen used internationally and in Canadian practice is 60 mg orally every 4 hours for 21 consecutive days, started within 96 hours of the haemorrhagic event.

• q4h: every four hours.
• NG: nasogastric.

If the patient is unconscious, use oral solution via nasogastric tube rather than crushing capsules when possible.

Missed-dose advice is to take as soon as remembered unless it is almost time for the next dose; do not double-dose.

In overdose, monitor vitals and provide supportive care for severe hypotension and bradycardia.

Pharmacist checklist: confirm start time post-SAH, reconcile concurrent medications, and document NG administration technique if applicable.

Interactions Overview

Concerned about interactions with other drugs or foods?

The primary pharmacologic concern is CYP3A4 interactions; strong inhibitors such as ketoconazole, itraconazole and clarithromycin increase nimodipine exposure and raise hypotension risk.

• Top Interacting Drug Classes: Strong CYP3A4 inhibitors (certain azole antifungals, macrolide antibiotics), some HIV protease inhibitors.
• Antihypertensives: Concomitant ACE inhibitors or beta-blockers can additively lower blood pressure and cause bradycardia.
• Food Interactions: Grapefruit and grapefruit juice may increase nimodipine levels and should be avoided.

Also counsel patients about alcohol content in some oral solutions, which is relevant to recovery programs and cultural restrictions.

Medication reconciliation at discharge is important and pharmacists should flag interactions in provincial drug databases and provide bilingual interaction warnings on labels.

Do not combine nimodipine with intravenous administration forms; IV dosing has caused severe harm.

Cultural Perceptions And Patient Habits In Canada

What do Canadian patients most often worry about when prescribed nimodipine?

Common concerns include clear bilingual information, outpatient cost despite hospital care being covered, hypotension at home, and alcohol content of some oral solutions.

• Rural and remote communities worry about timely access to oral solution formulations and continuity of supply after discharge.
• Indigenous and recovery communities may be particularly concerned about alcohol in liquid formulations.
• Patients increasingly prefer telepharmacy counselling and written bilingual (EN/FR) discharge instructions.

Practical actions for clinicians and pharmacists are to confirm a community pharmacy contact before discharge, prepare bilingual medication sheets, and explore provincial compassionate-supply routes if standard dispensing is delayed.

Some Canadians consider US sourcing for Nymalize; counsel patients about regulatory differences, shipping rules and insurance limitations when they ask.

Availability And Pricing Patterns

How easy is it to get nimodipine in Canada and what will it cost?

Nimodipine is prescription-only and is commonly stocked by hospital formularies for inpatient SAH care, while community availability depends on supplier networks and DIN listings.

Pricing patterns vary by province and by whether provincial plans require prior authorization; pharmacists should assist with ODB, BC PharmaCare or RAMQ applications when needed.

For patients in remote areas, arrange an initial community supply (7–14 days) at discharge and a follow-up dispensing plan with the receiving pharmacy.

In our online pharmacy, nimotop is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Storage instructions are to keep nimodipine below 25°C and protected from light.

Comparable Medicines And Preferences

Are there alternatives to nimodipine for preventing cerebral vasospasm after SAH?

There is no direct pharmacologic equivalent to nimodipine for post-SAH cerebral vasospasm that is approved.

Clinical preference in Canada remains nimodipine for reducing delayed ischemia after SAH, and any switch to other dihydropyridines for SAH management should require neurosurgical or stroke-team input.

When choosing formulation, consider capsule versus oral solution for NG use and alcohol content of solutions for sensitive populations.

Document rationale if an alternative is used and inform the neurosurgical team promptly.

Frequently Asked Questions

What do patients ask most often about nimodipine after discharge?

1. Is Nimotop/Nimodipine available in Canada?

   Many Canadian hospitals use nimodipine for SAH; community availability depends on DIN listing and provincial formulary status, so check with your pharmacist or the Health Canada database.

2. Can nimodipine be given intravenously?

   No — IV administration is contraindicated and associated with severe harm and death.

3. Will provincial drug plans cover it after discharge?

   Coverage varies by province; Ontario Drug Benefit, BC PharmaCare and RAMQ may require prior authorization, and pharmacists can help with applications.

4. What if I miss a dose?

   Take the missed dose as soon as you remember unless it is almost time for the next dose; do not double up.

5. Is the oral solution safe for people avoiding alcohol?

   Some oral solutions contain alcohol; ask your pharmacist for product specifics or request an alcohol-free alternative if available.

• Emergency Signs: severe dizziness, fainting, chest pain, or very low blood pressure require urgent medical attention.

Guidelines For Proper Use

What should pharmacists and patients check before and after discharge?

Pharmacist checklist for discharge and community care includes confirming DIN and supplier, providing a bilingual (EN/FR) medication guide, arranging an initial community supply of 7–14 days, and counselling on the 60 mg q4h ×21 days regimen.

Additional pharmacist tasks are to review CYP3A4 and antihypertensive interactions, document alcohol content of the oral solution, and set up a blood-pressure monitoring plan for the first 48–72 hours.

Patient instructions should advise taking nimodipine every four hours around the clock (set alarms), reporting dizziness or fainting, not stopping abruptly, and bringing a medication list to follow-up appointments.

For rural or remote patients, coordinate with the local pharmacy or telepharmacy to ensure uninterrupted supply and consider provincial exceptional-access or compassionate-supply pathways when standard dispensing is delayed.

Data highlights to reinforce: start within 96 hours of SAH, continue for 21 days, and use oral administration only.

Always verify the local summary of product characteristics (SmPC) and Health Canada/DIN status for the exact product dispensed.

Delivery Across Canada (English)